SCHEMBL9964831

SCHEMBL9964831

CC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4Cc5cccnc5C4)cc3C[C@@H]12

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.52
MAOB P27338 4/20 0.52
CYP2C19 P33261 1/20 0.52
KCNH2 Q12809 2/20 0.41
PTGS1 P23219 2/20 0.38
SDHA P31040 2/20 0.38
LMNA P02545 1/20 0.38
CALML3 P27482 1/20 0.38
GRM1 Q13255 1/20 0.36
TIPARP Q7Z3E1 1/20 0.36
HDAC6 Q9UBN7 1/20 0.35
IRAK4 Q9NWZ3 3/20 0.32
NAMPT P43490 1/20 0.32
F10 P00742 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9964811 0.92 MAOA (0.43) MAOAMAOBCYP2C19KCNH2GRM1
SCHEMBL9929931 0.86 KCNH2 (0.43) MAOAMAOBCYP2C19KCNH2PTGS1
SCHEMBL9930565 0.85 MAOA (0.52) MAOAMAOBCYP2C19KCNH2PTGS1
SCHEMBL14069343 0.85 MAOA (0.52) MAOAMAOBCYP2C19KCNH2PTGS1
SCHEMBL9964880 0.81 MAOA (0.59) MAOAMAOBCYP2C19KCNH2PTGS1
SCHEMBL9964792 0.81 MAOA (0.59) MAOAMAOBCYP2C19KCNH2PTGS1
SCHEMBL9964832 0.81 MAOA (0.47) MAOAMAOBCYP2C19KCNH2PTGS1
SCHEMBL9964827 0.80 MAOA (0.40) MAOAMAOBKCNH2TIPARP
SCHEMBL9968730 0.80 MAOA (0.57) MAOAMAOBCYP2C19KCNH2PTGS1
SCHEMBL14069406 0.79 MAOA (0.49) MAOAMAOBCYP2C19PTGS1SDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157434-A1 Antimicrobial heterocyclic compounds for treatment of bacterial infections CSO of MicuRx Pharmaceuticals, Inc. 2012-06-21 US disclosed
US-20120157434-A1 Antimicrobial heterocyclic compounds for treatment of bacterial infections CSO of MicuRx Pharmaceuticals, Inc. 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157434-A1 Antimicrobial heterocyclic compounds for treatment of bacterial infections NISCH, NOD1, NQO1 MAOA 1058/4885MAOB 761/4885CYP2C19 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.